Stable Isotope Labelled Compounds Market Report 2021-2031

10 February 2021

Visiongain has published a new report on Stable Isotope Labelled Compounds Market Report 2021-2031: Forecasts by Type (Carbon 13, D, Oxygen 18, N15), Application (Research, Clinical Diagnostics, Industrial), End User (Pharmaceutical & Biopharmaceutical Companies, Academic institute). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

GlobalStable Isotope labelled Compounds market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031. The growth of this market is driven predominantly by the upsurge in research activities in the pharmaceutical and biotechnology sector, rising proteomics research, and the increasing pervasiveness of cancer.

Isotopic labelling is a technique used to track the passage of an isotope through a reaction metabolic pathway, or cell. The reactant is labelledby replacing specific atoms by their isotope. The reactant is then allowed to sustain the reaction. The position of the isotopes in the products is measured to determine the sequence the isotopic atom followed in the reaction or the cells metabolic passageway. The nuclides used in isotopic labelling may be stable nuclides or radionuclides. In the latter case, the labelling is called radiolabelling

COVID-19 Impact on Stable Isotope labelled Compounds Market
In this occurrence of corona virus and the threat of lives is increasing all over the world, several companies are trying hard for the better medicines and harder to get vaccines. For this process several countries are undergoing with several researches and testing. For this research processes isotope labelling is most important, so this market is getting boosted with a high speed.
Market Drivers
The growth of this market is driven majorly by the increase in research activities in the pharmaceuticals and biotechnology sector, rising proteomics research, and the rising chances of cancer, however the high cost of stable isotopes labelled compounds is expected to restrict the growth of this market.
Market Opportunities
On the basis of end users, the stable isotope labelled compounds market is classified into pharmaceutical and biotechnology companies, hospitals and diagnostic centres, academic and research institutes. But among these the pharmaceuticals and biotechnology companies will grow higher than all, owing to the upsurge in the chemicals and pharmaceuticals demand backed by huge R&D investments. This growth in-turn is directed towards the exploration of potential capability for the Isotope labelled Compounds Market.

Competitive Landscape
GlobalStable Isotope labelled Compounds market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships,acquisitions and others to increase their footprints in this market. Some of companies mentioned-PerkinElmer Inc. (US),Merck KGaA (Germany),Cambridge Isotope Laboratories, Inc. (US),URENCO Limited (UK), IsoSciences, LLC (US) ,Medical Isotopes, Inc. (US) ,Omicron Biochemicals, Inc. (US), Trace Sciences International (US), Alsachim (France), Taiyo Nippon Sanso Corporation (Japan), PerkinElmer (US), Rotem Industries Israel Ltd. (Israel), CortecNet (France, ISOFLEX (US), Huayi Isotopes Co(Canada) Mesbah Energy Co. (Iran), Shanghai Research Institute Of Chemical Industry (China), 3C Molecular, Inc. (US), C/D/N/ Isotope Inc. (Canada), Shoko Co. Ltd. (Japan).

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021


Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021